课题基金 / 基金详情

CCTN - CLINICAL EVALUATION OF LONG ACTING REVERSIBLE CONTRACEPTIVES

CCTN - CLINICAL EVALUATION OF LONG ACTING REVERSIBLE CONTRACEPTIVES
CCTN - 长效可逆避孕药的临床评估
批准号:
9915350
负责人:
ALISON EDELMAN
金额:
$6.97万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-25 至 2020-07-31

项目摘要

项目成果

ALISON EDELMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To evaluate contraceptive efficacy, pain of insertion, bleeding patterns, associate cramping, expulsion rates as well as other safety and side effects of the long acting reversible contraceptive (LARCs) in women of reproductive age. The Contraceptive Discovery and Development Branch (CDDB) under the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is committed to develop new methods that are long acting reversible contraceptives that can provide safe and effective contraception for women who may have risk factors against some contraceptive products as well as reduce the risk of venous thromboembolism (VTE). The copper intrauterine devices (IUDs) are example of intrauterine systems that provide long acting contraceptive benefits without exogenous hormones or disruption of the regular menstrual cycle.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CENTRAL LABORATORY FOR PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
CENTRAL LABORATORY FOR PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
CENTRAL LABORATORY FOR PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION
CCTN - CLINICAL EVALUATION OF LONG ACTING REVERSIBLE CONTRACEPTIVES
海外基金